Novel Piperazine Derivatives of Vindoline as Anticancer Agents
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147929 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Bernadett Zsoldos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Mű…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cricetulus, Piperazines, Cell Proliferation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A series of novel vindoline–piperazine conjugates were synthesized by coupling 6 N-substituted piperazine pharmacophores at positions 10 and 17 of Vinca alkaloid monomer vindoline through different types of linkers. The in vitro antiproliferative activity of the 17 new conjugates was investigated on 60 human tumor cell lines (NCI60). Nine compounds presented significant antiproliferative effects. The most potent derivatives showed low micromolar growth inhibition (GI50) values against most of the cell lines. Among them, conjugates containing [4-(trifluoromethyl)benzyl]piperazine (23) and 1-bis(4-fluorophenyl)methyl piperazine (25) in position 17 of vindoline were outstanding. The first one was the most effective on the breast cancer MDA-MB-468 cell line (GI50 = 1.00 μM), while the second one was the most effective on the non-small cell lung cancer cell line HOP-92 (GI50 = 1.35 μM). The CellTiter-Glo Luminescent Cell Viability Assay was performed with conjugates 20, 23, and 25 on non-tumor Chinese hamster ovary (CHO) cells to determine the selectivity of the conjugates for cancer cells. These compounds exhibited promising selectivity with estimated half-maximal inhibitory concentration (IC50) values of 2.54 μM, 10.8 μM, and 6.64 μM, respectively. The obtained results may have an impact on the design of novel vindoline-based anticancer compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
- Spectroscopic Research Department, Gedeon Richter Plc., P.O. Box 27, H-1475 Budapest, Hungary.
- Department of Pharmacology and Pharmacotherapy, Medical School & Centre for Neuroscience, University of Pécs, H-7624 Pécs, Hungary.
- National Laboratory for Drug Research and Development, H-1117 Budapest, Hungary.
- HUN-REN PTE Chronic Pain Research Group, H-7624 Pécs, Hungary.
ORCID-Profile: Miklós Dékány
Zitieren
APA
Zsoldos, B., Nagy, N., Donkó-Tóth, V., Keglevich, P., Weber, M., Dékány, M., Nehr-Majoros, A., Szőke, É., Helyes, Z., & Hazai, L. (2024). Novel Piperazine Derivatives of Vindoline as Anticancer Agents. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147929
Vancouver
Zsoldos B, Nagy N, Donkó-Tóth V, Keglevich P, Weber M, Dékány M, et al. Novel Piperazine Derivatives of Vindoline as Anticancer Agents. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147929
BibTeX
@article{Zsoldos2024,
author = {Zsoldos, Bernadett and Nagy, Nóra and Donkó-Tóth, Viktória and Keglevich, Péter and Weber, Márton and Dékány, Miklós and Nehr-Majoros, Andrea and Szőke, Éva and Helyes, Zsuzsanna and Hazai, László},
title = {Novel Piperazine Derivatives of Vindoline as Anticancer Agents},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147929}
}
EUVIMED